Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Age and acute myeloid leukemia.

Frederick R Appelbaum1, Holly Gundacker, David R Head

  • 1Southwest Oncology Group, Operations Office, 14980 Omicron Dr, San Antonio, TX 78245-3217, USA.

Blood
|February 4, 2006
PubMed
Summary

Acute myeloid leukemia (AML) biology and outcomes significantly worsen with age. Older patients show increased unfavorable cytogenetics and poorer treatment responses, necessitating age-specific therapeutic evaluations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer CARE (Connected Access and Remote Expertise) Beyond Walls - Safety, Feasibility, and Patient Experience of Home-Based Chemotherapy.

NEJM catalyst innovations in care delivery·2026
Same author

A Model for Clinician and Staff Education in the Engagement of American Indians in Genomic Research.

Journal of cancer education : the official journal of the American Association for Cancer Education·2026
Same author

A Multiregional Decentralized Clinical Trial Program to Improve Access.

JAMA network open·2026
Same author

Prognostic impact of age and MDS-associated mutations in <i>NPM1</i> -mutated AML.

medRxiv : the preprint server for health sciences·2025
Same author

Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapy.

Blood neoplasia·2025
Same author

Erratum: Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia.

JCO oncology practice·2025

Area of Science:

  • Hematology
  • Oncology
  • Geriatric Medicine

Background:

  • Acute myeloid leukemia (AML) is a heterogeneous disease.
  • Age is a critical factor influencing AML biology and patient outcomes.
  • Understanding age-related changes in AML is crucial for optimizing treatment strategies.

Purpose of the Study:

  • To investigate how the biological and clinical characteristics of AML differ across age groups.
  • To evaluate the impact of age on treatment response and outcomes in AML patients.
  • To identify specific age-related factors associated with poor prognosis in AML.

Main Methods:

  • Retrospective analysis of 968 adult patients with AML.
  • Data collected from 5 Southwest Oncology Group clinical trials.

Related Experiment Videos

  • Comparison of clinical presentation, cytogenetics, multidrug resistance, and outcomes based on age.

    • Main Results:

    • Older AML patients exhibited poorer performance status, lower white blood cell counts, and fewer marrow blasts.
    • Multidrug resistance increased from 33% in younger patients (<56 years) to 57% in older patients (>75 years).
    • Favorable cytogenetics decreased from 17% to 4%, while unfavorable cytogenetics rose from 35% to 51% with increasing age, particularly involving chromosomes 5, 7, and 17.
    • Treatment outcomes deteriorated significantly with age within each cytogenetic risk group.
    • A combination of poor performance status and advanced age predicted a high likelihood of early mortality.

    Conclusions:

    • AML exhibits distinct age-related biological and clinical differences.
    • Increased unfavorable cytogenetics and age-related decline in performance status contribute to poorer outcomes in older adults.
    • Age-specific assessments are essential for evaluating and developing effective AML therapies.